Khasraw, M., Dun, M. D., Arrillaga-Romany, I., Verhaak, R. G. W., Bouffet, E., Hansford, J. R., … Wen, P. Y. (2026). Dordaviprone for Diffuse Midline Glioma: A Landmark Approval or a Premature Step? Neuro Oncol. https://doi.org/10.1093/neuonc/noag117

Khasraw, Mustafa, Matthew D. Dun, Isabel Arrillaga-Romany, Roel G. W. Verhaak, Eric Bouffet, Jordan R. Hansford, Kirit Singh, Sabine Mueller, Carl Koschmann, and Patrick Y. Wen. “Dordaviprone for Diffuse Midline Glioma: A Landmark Approval or a Premature Step?” Neuro Oncol, May 22, 2026. https://doi.org/10.1093/neuonc/noag117.

Khasraw M, Dun MD, Arrillaga-Romany I, Verhaak RGW, Bouffet E, Hansford JR, et al. Dordaviprone for Diffuse Midline Glioma: A Landmark Approval or a Premature Step? Neuro Oncol. 2026 May 22;

Khasraw, Mustafa, et al. “Dordaviprone for Diffuse Midline Glioma: A Landmark Approval or a Premature Step?” Neuro Oncol, May 2026. Pubmed, doi:10.1093/neuonc/noag117.

Khasraw M, Dun MD, Arrillaga-Romany I, Verhaak RGW, Bouffet E, Hansford JR, Singh K, Mueller S, Koschmann C, Wen PY. Dordaviprone for Diffuse Midline Glioma: A Landmark Approval or a Premature Step? Neuro Oncol. 2026 May 22;